Typically, viral infections are not desirable; however, bacterial viruses, or bacteriophages, are promising therapeutic agents against multi-drug resistant microbes. Many phages have a narrow host range, infecting only one bacterial species or strain. Researchers hope to transform these viruses into targeted therapies for devastating bacterial infections. In this webinar from The Scientist, bacteriophage experts Paul Turner and Jason Gill will describe their research on phages that destroy drug resistant pathogens, their experiences with emergency patient treatment, and challenges and successes in obtaining FDA approval for this experimental therapy.
Topics to be covered
- Genomics and distribution of Staphylococcus, Burkholderia, and Klebsiella species
- Circumventing bacterial phage resistance
- Phages in emergency patient treatment
- Regulatory considerations surrounding clinical phage use
Meet the Speakers:
Paul Turner, PhD
Rachel Carson Professor of Ecology & Evolutionary Biology...
Jason Gill, PhD
Center for Phage Technology
Associate Professor, Departments of Animal Science, Microbial Pathogenesis and Immunology, and Genetics
Texas A&M University